Institutul Privat de Cercetari Melchisedec, pentru Boli Autoimune, Ereditare si Rare - IPCM

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Depression3 trials
• Schizophrenia2 trials

Phase

• Phase 35 trials

Status

• Completed3 trials
• Recruiting2 trials

Lead sponsor

• Neurocrine Biosciences3 trials
• Janssen Cilag International1 trial
• Neurocrine Biosciences Inc.1 trial

Running trials

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06911112· Phase 3· Neurocrine Biosciences· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression2 recruiting

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Completed

  Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

  2022-502233-25-00· Phase 3· Neurocrine Biosciences Inc.· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Neurocrine Biosciences· Source